Lantheus Increases to 12.16% shareholding in Radiopharm with US$5m (A$8m) Placement
10 janv. 2025 08h00 HE
|
Radiopharm Theranostics
Private placement to radiopharmaceutical industry leader Lantheus, for US$5.0 millionPlacement at A$0.060 per share, representing a premium of 150% to the last closing price of A$0.024Lantheus...
Radiopharm Announces Strategic Co-Development Partnership with Lantheus for Australia
30 déc. 2024 08h00 HE
|
Radiopharm Theranostics
RAD to advance the clinical development of Lantheus innovative radiopharmaceuticals in Australia Initial collaboration will focus on a Phase 1 imaging trialFinancial incentives to be paid to RAD upon...
RAD 202 Receives Approval to Start Phase 1 Therapeutic Trial
20 déc. 2024 08h00 HE
|
Radiopharm Theranostics
Ethics approval received in Australia for the initiation of RAD’s Phase 1 therapeutic trial of 177Lu-RAD202 in Breast and Gastric CancersThe Phase 1 First-In-Human study is designed to assess the...
Radiopharm Achieves Nasdaq Listing of American Depositary Shares
27 nov. 2024 08h00 HE
|
Radiopharm Theranostics
Trading under ticker symbol RADXComplements existing US shareholders (currently holding 21% of Radiopharm)No associated capital raisingModest admin & financial compliance overheads SYDNEY, Nov. ...
Radiopharm Receives Strategic Investment for up to A$18 million
20 juin 2024 20h41 HE
|
Radiopharm Theranostics
Lantheus has agreed to make an initial strategic equity investment of A$7.5 million in RadiopharmOffer price for the shares of A$0.05 represents a 47% premium to the last closing price of $0.034 on 19...
RAD receives approval for Phase 1 therapeutic study of PDL1-nanobody in Non-Small Cell Lung Cancer
09 oct. 2023 07h27 HE
|
Radiopharm Theranostics
SYDNEY, Australia, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic...
Radiopharm Theranostics Expands Supply Agreement With TerThera for Terbium-161 Isotope Use in Prostate Cancer
24 août 2023 08h00 HE
|
Radiopharm Theranostics
SYDNEY, Australia, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of radiopharmaceutical products for both diagnostic and therapeutic...
Radiopharm Theranostics Receives FDA Orphan Drug Designation for Trivehexin (RAD 301) in Pancreatic Cancer
09 mai 2023 07h30 HE
|
Radiopharm Theranostics
Trivehexin radiopharmaceuticals being developed for imaging and treatment of cancers expressing αvβ6-integrinPancreatic ductal adenocarcinoma is primary indication due to high unmet needPotential...
Radiopharm Theranostics Enters Into Supply Agreement with TerThera for Terbium-161 Isotope
17 avr. 2023 07h30 HE
|
Radiopharm Theranostics
SYDNEY, Australia, April 17, 2023 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of radiopharmaceutical products for both diagnostic and...
Radiopharm Theranostics Invited to Participate in Jefferies Radiopharma Innovation Summit
28 mars 2023 07h30 HE
|
Radiopharm Theranostics
SYDNEY, Australia, March 28, 2023 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of radiopharmaceutical products for both diagnostic and...